Content by Connie Karambelas
The recently decoded zebra finch genome is expected to give scientists and researchers more insight into human speech disorders and treatment, researchers are reporting.
A federal district court judge effectively voided the monopoly on breast cancer gene testing and leaves the rest of the human genome up for a squabble.
The ruling by New York District Court Judge Robert Sweet has stripped Utah-based Myriad Genetics of the patent on the BRCA 1 and BRCA2 genes, opening the door for rivals to offer testing. Myriad plans to appeal the ruling. All breast cancer gene testing in the country has been performed by Myriad up until now.